Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: A redox/polyamine-dependent effect

Liqun Huang, Caihua Zhu, Yu Sun, Gang Xie, Gerardo Mackenzie, George Qiao, Despina Komninou, Basil Rigas

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Non-steroidal anti-inflammatory drugs such as sulindac are promising chemoprevention agents against colon cancer, but their weak potency and side effects limit their use for both chemoprevention and chemotherapy. Here, we evaluated the effect of a new sulindac derivative, phospho-sulindac or OXT-922, on the growth of human cancer cell lines and its mechanism of action. OXT-922 inhibited the growth of human cancer cell lines originating from colon, pancreas and breast ∼11- to 30-fold more potently than sulindac. This effect was mediated by a strong cytokinetic effect. Compared with control, OXT-922 inhibited cell proliferation by up to 67%, induced apoptosis 4.1-fold over control and blocked the G1 to S cell cycle phase transition. OXT-922 suppressed the levels of cell cycle regulating proteins, including cyclins D1 and D3 and Cyclin-dependent kinases (CDK) 4 and 6. The levels of intracellular reactive oxygen species (ROS), especially those of mitochondrial O2•-, were markedly elevated (5.5-fold) in response to OXT-922. ROS collapsed the mitochondrial membrane potential and triggered apoptosis, which was largely abrogated by antioxidants. OXT-922 suppressed nuclear factor-kappaB activation and downregulated thioredoxin-1 expression. It also suppressed the production of prostaglandin E2 and decreased cyclooxygenase-1 expression. Similar to sulindac, OXT-922 enhanced spermidine/spermine N1-acetyltransferase activity, reduced the cellular polyamine content and synergized with difluoromethylornithine to inhibit cancer cell proliferation and induce apoptosis. Our results suggest that OXT-922 possesses promising anticancer properties and deserves further evaluation.

Original languageEnglish (US)
Pages (from-to)1982-1990
Number of pages9
JournalCarcinogenesis
Volume31
Issue number11
DOIs
StatePublished - Nov 1 2010
Externally publishedYes

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: A redox/polyamine-dependent effect'. Together they form a unique fingerprint.

  • Cite this